Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.68 |
| ▸ | NPY4R | P50391 | 8/20 | 0.68 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.68 |
| ▸ | NPY1R | P25929 | 6/20 | 0.68 |
| ▸ | KDM1A | O60341 | 3/20 | 0.65 |
| ▸ | CALCR | P30988 | 3/20 | 0.65 |
| ▸ | TFPI | P10646 | 4/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | KDM5A | P29375 | 1/20 | 0.63 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29854460 | 1.00 | NPY2R (0.68) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL29369173 | 1.00 | NPY2R (0.68) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL30658322 | 0.93 | NPY2R (0.68) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL31182587 | 0.91 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL31105560 | 0.91 | NPY2R (0.72) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL29530680 | 0.90 | CALCR (0.67) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31547377 | 0.90 | NPY2R (0.65) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL31182542 | 0.90 | NPY2R (0.69) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30495624 | 0.90 | NPY2R (0.64) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL30607383 | 0.90 | CALCR (0.67) | NPY2RNPY4RNPY5RNPY1RKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850263-B2 | Nanoparticles conjugated with vasoactive intestinal peptide antagonists | EMORY UNIVERSITY (US) | 2023-12-26 | — | — | US | claimed |
| US-20230190865-A1 | VIP Antagonists and Uses in Treating Cancer | GEORGIA TECH RESEARCH CORPORATION | 2023-06-22 | — | — | US | claimed |
| US-11471506-B2 | VIP antagonists and uses in treating cancer | EMORY UNIVERSITY (US) | 2022-10-18 | — | — | US | claimed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250122258-A1 | COMPOSITIONS AND USES OF VASOACTIVE INTESTINAL PEPTIDE (VIP) ANTAGONISTS | EMORY UNIVERSITY | 2025-04-17 | — | — | US | disclosed |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES INC (US) | 2025-01-23 | — | — | US | disclosed |
| US-12098180-B2 | Compositions and uses of vasoactive intestinal peptide (VIP) antagonists | EMORY UNIVERSITY (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240271092-A1 | Methods of Treating Cancer and Infectious Diseases Using Cell Based Therapies | EMORY UNIVERSITY | 2024-08-15 | — | — | US | disclosed |
| WO-2023081835-A1 | EXPANDING T-CELL USING MITOFUSIN ACTIVATORS AND USES IN CANCER THERAPIES | EMORY UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| WO-2022245820-A1 | VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR ANTAGONISTS | EMORY UNIVERSITY (US) | 2022-11-24 | — | — | WO | disclosed |
| US-11471506-B2 | VIP antagonists and uses in treating cancer | EMORY UNIVERSITY (US) | 2022-10-18 | — | — | US | disclosed |
| US-11464855-B2 | Antagonism of the VIP signaling pathway | EMORY UNIVERSITY (US) | 2022-10-11 | — | — | US | disclosed |
| CN-115094036-A | Methods of treating cancer and infectious diseases using cell-based therapies | 爱默蕾大学 | 2022-09-23 | — | — | CN | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| CN-108778312-B | Methods of treating cancer and infectious diseases using cell-based therapies | 爱默蕾大学 | 2022-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | NPY2R 4092/4885NPY4R 2463/4885NPY5R 3969/4885 |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | NPY2R 3040/4885NPY4R 3418/4885NPY5R 3095/4885 |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | NPY2R 2488/4885NPY4R 1339/4885NPY5R 1218/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | NPY2R 2690/4885NPY4R 2564/4885NPY5R 2014/4885 |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | EIF2AK2, ACE2, SARS1 | NPY2R 2282/4885NPY4R 3585/4885NPY5R 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.